Navigation Links
SureClinical Announces SureClinical Certified Cloud™ for North America and Europe

Rancho Cordova, California (PRWEB) November 27, 2013

With the continued escalation of drug development costs, BioPharma organizations are increasingly considering cloud computing applications as a means to improve operational efficiencies and to accelerate time to market. In the highly regulated drug development market, health science cloud applications must comply with and be validated against a growing list of global government requirements. US and EU requirements such as FDA 21 CFR Part 11, HIPAA, European Commission Privacy Directives and US FDA electronic signing regulations make it costly, time consuming and difficult for organizations to deploy internally developed applications that adhere to regulatory requirements. To address compliance needs and to accelerate time to value, SureClinical launched SureClinical Certified Cloud™ to give its life science and healthcare customers immediate access to the operational efficiencies and return on investment offered with its SureTrial suite of clinical trial applications.

SureClinical's SureTrial eTMF cloud solution is a suite of cloud-based applications delivered on the SureClinical Certified Cloud, purpose-built for clinical trials and validated against US and EU regulatory requirements. SureClinical has Certified Cloud data center operations in regional centers throughout North America and in Europe. The European Certified Cloud data centers meet the privacy standards of the European Commission's Directive on Data Protection.

"We are very excited to meet our customers’ demands for a highly secure, compliant and validated suite of cloud solutions purpose-built for health sciences. SureClinical’s Certified Cloud with its FDA-compliant SureTrial eTMF cloud application suite will enable BioPharma firms to confidently move mission-critical clinical trial operations business processes to the cloud without compromising security, performance, or reliability, while at the same time maintaining compliance with government regulatory requirements. We are committed to helping BioPharma firms enhance operational efficiency through the cloud," said Zachariah Schmidt, President and CEO, SureClinical.

With the SureClinical Certified Cloud platform and SureClinical’s SureTrial suite of clinical applications, SureClinical provides BioPharma organizations with a secure, agency compliant platform that helps them to realize new operational efficiencies.

SureClinical Certified Cloud Compliance and Security Features

The combination of SureClinical’s Certified Cloud platform and its SureTrial eTMF application suite provides the premier product, support and services clinical trial organizations need to transition to the cloud, while addressing the demanding and unique security, compliance and operational requirements of the BioPharma sector. SureClinical Certified Cloud supports industry compliance. A partial set of cloud compliance and security features are listed below:

  • Physical segregation of customer data: SureClinical has optimized its fast virtualized server environment to ensure rapid deployment while meeting the most strenuous requirements of FDA 21 CFR Part 11 for protection of clinical trial data. SureClinical’s physical segregation of customer data approach maximizes the efficiency of cloud infrastructure while delivering the highest levels of cloud data privacy and security.
  • Two-factor authentication: SureClinical’s Certified Cloud provides integrated two-factor authentication for electronic signing (pat pending) as well as strong authentication techniques to verify user identification and limit system access per FDA and EU regulations.
  • FIPS-140-2 Level 3 compliance: SureClinical’s Certified Cloud is the first cloud solution for health sciences to offer a secure cloud-based digital signing service that enables investigators to electronically sign documents outside the firewall making the 100% paperless eTMF a physical reality. Our patent-pending signing services support digital certificate signing (PKI x.509). All PKI signing transactions utilize US NIST tested and approved FIPS-140-2 Level 3 technologies.
  • Audit trail: All cloud instances include an exportable, read-only time-stamped audit trail that adheres to FDA requirements for user activity and electronic signing events.
  • Continuous infrastructure monitoring: Proactive infrastructure monitoring, 24x7 throughout our global certified cloud platform to insure uninterrupted service.
  • Security audits: Quarterly PCI system scans and security audits are conducted to ensure security compliance.
SureClinical Cloud Certifications

The technology infrastructure underlying the SureClinical Certified Cloud provides customers with the most comprehensive list of government regulatory validations and certifications in the industry, as well as the infrastructure to support extreme performance, scalability, availability and security needed to run mission-critical, health science specific solutions:

  • SSAE-16 Type I and Type II Attestation: Support for both SSAE-16 Type I and Type II attestations in conjunction with auditor SSAE 16 Solutions.
  • PCI Compliance: Maintenance of a PCI-compliant environment. Certification is optional for customers who purchase the PCI compliance service.
  • HIPAA Business Associate: SureClinical maintains policies and procedures necessary to act as a HIPAA Business Associate for customers whose application maintains data covered by HIPAA regulations.
  • FDA CFR Part 11 Application Certification: SureClinical’s SureTrial eTMF cloud application is independently audited and validated through an ongoing program of continuous validation and certification. These in-depth evaluations of our cloud applications and cloud infrastructure are done against a rigorous set of FDA regulations.
  • U.S. Commerce Department Safe Harbor Certification: SureClinical’s cloud is certified under the U.S Commerce Department’s Safe Harbor program, which signifies that the SureClinical cloud employs policies and procedures that meet the privacy standards of the European Commission's Directive on Data Protection. By certifying under the program, SureClinical’s customers can be assured that their personal information is private and protected.
About SureClinical

Headquartered in Northern California, SureClinical is the premier provider of health science content management software applications for BioPharma. SureClinical’s mobile health science content management solutions run on Android®, Apple® iPad, Apple® IOS, and other popular smartphone platforms, as well as on all major web browsers. For more information, visit

Copyright © 2013 SureClinical. All rights reserved. SureClinical, SureEsign, SureTrial, and the SureTrial logo are trademarks of SureClinical. Other names used herein may be trademarks of their respective owners.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. SureClinical Announces SurePortal™, First 100% Paperless eTMF Investigator Portal for Automated Document Completion Across Mobile, Web
2. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
3. GLM Displays Announces Sale on Popular Mosquito 800 Retractable Banner Stand
4. Medrio Announces Advanced Research Associates to Join Partner Program
5. Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
6. Elsevier Announces the Launch of Open Access Journal: Case Studies in Construction Materials
7. RPS Announces FDA Clearance of Rapid, Point-of-Care Test for Dry Eye Disease – InflammaDry®
8. Goodmark Medical announces joining the American Chiropractic Association’s (ACA) Corporate Member Program
9. ISPE Announces Recipients of 2013 International Honor Awards at Global Annual Meeting
10. Ceres Announces Fiscal Year 2013 Financial Results
11. National Association of Professional Women Announces Michelle Doss, Director, Fujifilm Diosynth Biotechnology, as VIP Woman of the Year
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... has published a new market report titled  Gesture Recognition ... and Forecast, 2015 - 2021. According to the report, the global ... and is anticipated to reach US$29.1 bn by 2021, ... North America dominated the ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):